Get the Stockscreener App
12.61
6.52%
-0.88
After Hours:
12.87
0.26
+2.06%
Adaptive Biotechnologies Corp stock is traded at $12.61, with a volume of 1.95M.
It is down -6.52% in the last 24 hours and down -0.39% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$13.49
Open:
$13.54
24h Volume:
1.95M
Relative Volume:
0.95
Market Cap:
$1.92B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-9.4104
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-1.87%
1M Performance:
-0.39%
6M Performance:
+65.49%
1Y Performance:
+193.26%
1-Day Range:
$12.60
$13.63
1-Week Range:
$12.34
$13.68
52-Week Range:
$3.981
$13.68
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
12.61 | 1.89B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies stock hits 52-week high at $13.53 By Investing.com - Investing.com Nigeria
Published on: 2025-09-12 01:32:59 - Newser
What does recent volatility data suggest for Adaptive Biotechnologies Corporation2025 Market Overview & Verified Swing Trading Watchlists - Newser
Adaptive Biotechnologies stock hits 52-week high at $13.53 - Investing.com
Published on: 2025-09-11 05:04:12 - Newser
How institutional ownership impacts Adaptive Biotechnologies Corporation stockJuly 2025 Reactions & Growth Focused Stock Reports - Newser
Using Python tools to backtest Adaptive Biotechnologies Corporation strategiesPortfolio Return Report & Real-Time Buy Zone Alerts - Newser
Adaptive Biotechnologies at Morgan Stanley Conference: Strategic Growth Insights - Investing.com
Full technical analysis of Adaptive Biotechnologies Corporation stockLayoff News & Long-Term Growth Stock Strategies - Newser
How to forecast Adaptive Biotechnologies Corporation trends using time series2025 Major Catalysts & Smart Money Movement Alerts - Newser
Can Adaptive Biotechnologies Corporation rally from current levelsWeekly Loss Report & Risk Managed Investment Strategies - Newser
Is it too late to sell Adaptive Biotechnologies CorporationMarket Movement Recap & Safe Entry Momentum Tips - Newser
Market reaction to Adaptive Biotechnologies Corporation’s recent news2025 Technical Overview & High Accuracy Swing Entry Alerts - Newser
Leading vs lagging indicators on Adaptive Biotechnologies Corporation performanceWeekly Market Summary & Safe Entry Zone Identification - Newser
What moving averages say about Adaptive Biotechnologies Corporation2025 Price Targets & Free Long-Term Investment Growth Plans - Newser
Visualizing Adaptive Biotechnologies Corporation stock with heatmapsPortfolio Value Report & Technical Pattern Alert System - Newser
How to recover losses in Adaptive Biotechnologies Corporation stockJuly 2025 Action & Fast Momentum Stock Entry Tips - Newser
Has Adaptive Biotechnologies Corporation found a price floorQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - Newser
How high can Adaptive Biotechnologies Corporation stock goWeekly Stock Analysis & AI Driven Stock Movement Reports - Newser
Hsbc Holdings PLC Has $256,000 Position in Adaptive Biotechnologies Corporation $ADPT - Defense World
Adaptive Biotechnologies down 5% after Genentech pact terminated - MSN
Multi asset correlation models including Adaptive Biotechnologies CorporationGlobal Markets & High Win Rate Trade Alerts - Newser
Real time scanner hits for Adaptive Biotechnologies Corporation explainedWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - Newser
What high frequency data says about Adaptive Biotechnologies Corporation2025 Geopolitical Influence & Weekly High Momentum Picks - Newser
Should you wait for a breakout in Adaptive Biotechnologies CorporationMarket Trend Review & Smart Allocation Stock Reports - Newser
Has Adaptive Biotechnologies Corporation formed a bullish divergence2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser
Published on: 2025-09-03 06:26:44 - Newser
Custom watchlist performance reports with Adaptive Biotechnologies Corporation2025 AllTime Highs & Risk Controlled Stock Alerts - Newser
Top chart patterns to watch in Adaptive Biotechnologies CorporationMarket Growth Summary & Short-Term Trading Opportunity Alerts - Newser
Candlestick signals on Adaptive Biotechnologies Corporation stock todayJobs Report & AI Forecast Swing Trade Picks - Newser
Developing predictive dashboards with Adaptive Biotechnologies Corporation data2025 Technical Patterns & Technical Confirmation Alerts - Newser
Is Adaptive Biotechnologies Corporation a top pick in the sectorMarket Risk Report & High Accuracy Swing Trade Signals - خودرو بانک
Does Adaptive Biotechnologies Corporation stock reflect fundamentalsWeekly Trade Summary & Reliable Price Action Trade Plans - خودرو بانک
Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice - Yahoo Finance
How Adaptive Biotechnologies Corporation stock reacts to Fed policy changesTrade Volume Report & Daily Entry Point Alerts - Newser
Regression analysis insights on Adaptive Biotechnologies Corporation performance2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Will Adaptive Biotechnologies Corporation rebound enough to break evenJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - Newser
Published on: 2025-08-30 22:39:14 - Newser
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):